Insufficient scRNA-seq data for expression of ETV4 at single-cell level.
Insufficient scRNA-seq data for expression of ETV4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 99% | 776.44 | 1790 / 1809 | 98% | 106.63 | 462 / 472 |
pancreas | 94% | 400.70 | 307 / 328 | 84% | 32.13 | 149 / 178 |
thymus | 96% | 396.77 | 625 / 653 | 79% | 40.63 | 476 / 605 |
lung | 93% | 219.98 | 538 / 578 | 79% | 40.30 | 907 / 1155 |
intestine | 51% | 106.17 | 490 / 966 | 94% | 90.45 | 493 / 527 |
esophagus | 55% | 308.19 | 789 / 1445 | 87% | 48.29 | 159 / 183 |
bladder | 57% | 108.95 | 12 / 21 | 80% | 50.84 | 404 / 504 |
stomach | 50% | 106.60 | 179 / 359 | 87% | 74.26 | 249 / 286 |
prostate | 97% | 446.93 | 238 / 245 | 5% | 41.85 | 25 / 502 |
ovary | 12% | 15.48 | 21 / 180 | 90% | 64.33 | 387 / 430 |
ureter | 0% | 0 | 0 / 0 | 100% | 26.30 | 1 / 1 |
kidney | 92% | 505.03 | 82 / 89 | 6% | 1.67 | 53 / 901 |
breast | 60% | 234.73 | 275 / 459 | 35% | 10.68 | 389 / 1118 |
uterus | 39% | 90.69 | 67 / 170 | 48% | 26.27 | 222 / 459 |
adrenal gland | 75% | 184.53 | 193 / 258 | 10% | 3.27 | 22 / 230 |
eye | 0% | 0 | 0 / 0 | 79% | 21.86 | 63 / 80 |
brain | 38% | 58.55 | 1005 / 2642 | 41% | 15.86 | 287 / 705 |
liver | 22% | 28.92 | 49 / 226 | 45% | 20.00 | 181 / 406 |
blood vessel | 59% | 111.62 | 789 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 56% | 17.63 | 25 / 45 |
heart | 55% | 123.42 | 476 / 861 | 0% | 0 | 0 / 0 |
muscle | 21% | 58.81 | 169 / 803 | 0% | 0 | 0 / 0 |
adipose | 20% | 27.71 | 238 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 19% | 234.77 | 175 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 17% | 4.53 | 5 / 29 |
spleen | 9% | 8.27 | 21 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030154 | Biological process | cell differentiation |
GO_0045618 | Biological process | positive regulation of keratinocyte differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005694 | Cellular component | chromosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0005515 | Molecular function | protein binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
Gene name | ETV4 |
Protein name | ETS translocation variant 4 (Adenovirus E1A enhancer-binding protein) (E1A-F) (Polyomavirus enhancer activator 3 homolog) (Protein PEA3) ETS variant transcription factor 4 (cDNA FLJ55351, highly similar to ETS translocation variant 4) ETS variant transcription factor 4 |
Synonyms | PEA3 E1AF |
Description | FUNCTION: Transcriptional activator . May play a role in keratinocyte differentiation . .; FUNCTION: (Microbial infection) Binds to the enhancer of the adenovirus E1A gene and acts as a transcriptional activator; the core-binding sequence is 5'-[AC]GGA[AT]GT-3'. . |
Accessions | ENST00000393664.6 [P43268-1] B7Z5F4 ENST00000591713.5 [P43268-1] K7EMW0 ENST00000545954.5 [P43268-2] P43268 ENST00000586764.1 ENST00000545089.5 ENST00000538265.5 [P43268-2] ENST00000586826.1 [P43268-3] ENST00000319349.10 [P43268-1] |